Effects of soy isoflavone on hepatic steatosis in high fat-induced rats
Soy isoflavone has benefits for metabolic syndrome but the mechanism is not completely understood. This study was designed to determine the effects of soy isoflavone on hepatic fat accumulation in non-alcoholic fatty liver disease (NAFLD) rats induced by high fat diet (HFD). Sprague-Dawley rats were...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
the Society for Free Radical Research Japan
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5612816/ https://www.ncbi.nlm.nih.gov/pubmed/28955124 http://dx.doi.org/10.3164/jcbn.16-98 |
_version_ | 1783266131785547776 |
---|---|
author | Liu, Huanhuan Zhong, Huijia Leng, Liang Jiang, Zhuoqin |
author_facet | Liu, Huanhuan Zhong, Huijia Leng, Liang Jiang, Zhuoqin |
author_sort | Liu, Huanhuan |
collection | PubMed |
description | Soy isoflavone has benefits for metabolic syndrome but the mechanism is not completely understood. This study was designed to determine the effects of soy isoflavone on hepatic fat accumulation in non-alcoholic fatty liver disease (NAFLD) rats induced by high fat diet (HFD). Sprague-Dawley rats were administrated with a normal fat diet (control), HFD (NAFLD model), HFD with 10 or 20 mg/kg soy isoflavone daily for 12 weeks. Hepatic and serum lipid contents, liver histopathological examination, serum alanine transaminase (ALT), protein and mRNA expression of sterol regulatory element binding protein (SREBP)-1c, fatty acid synthase (FAS), peroxisome proliferator-activated receptor (PPAR) α were assayed respectively. Our study found that soy isoflavone reduced HFD-induced lipid accumulation in liver, serum ALT and improved liver lobule structure. In addition, the expression of SREBP-1c and FAS was lower, whereas protein level of PPARα was higher in two soy isoflavone groups than that of the HFD group. Collectively, these results demonstrate that soy isoflavone is capable of alleviating hepatic steatosis and delaying the progression of NAFLD via inhibiting lipogenesis and promoting fatty acid oxidation in liver. |
format | Online Article Text |
id | pubmed-5612816 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | the Society for Free Radical Research Japan |
record_format | MEDLINE/PubMed |
spelling | pubmed-56128162017-09-27 Effects of soy isoflavone on hepatic steatosis in high fat-induced rats Liu, Huanhuan Zhong, Huijia Leng, Liang Jiang, Zhuoqin J Clin Biochem Nutr Original Article Soy isoflavone has benefits for metabolic syndrome but the mechanism is not completely understood. This study was designed to determine the effects of soy isoflavone on hepatic fat accumulation in non-alcoholic fatty liver disease (NAFLD) rats induced by high fat diet (HFD). Sprague-Dawley rats were administrated with a normal fat diet (control), HFD (NAFLD model), HFD with 10 or 20 mg/kg soy isoflavone daily for 12 weeks. Hepatic and serum lipid contents, liver histopathological examination, serum alanine transaminase (ALT), protein and mRNA expression of sterol regulatory element binding protein (SREBP)-1c, fatty acid synthase (FAS), peroxisome proliferator-activated receptor (PPAR) α were assayed respectively. Our study found that soy isoflavone reduced HFD-induced lipid accumulation in liver, serum ALT and improved liver lobule structure. In addition, the expression of SREBP-1c and FAS was lower, whereas protein level of PPARα was higher in two soy isoflavone groups than that of the HFD group. Collectively, these results demonstrate that soy isoflavone is capable of alleviating hepatic steatosis and delaying the progression of NAFLD via inhibiting lipogenesis and promoting fatty acid oxidation in liver. the Society for Free Radical Research Japan 2017-09 2017-07-20 /pmc/articles/PMC5612816/ /pubmed/28955124 http://dx.doi.org/10.3164/jcbn.16-98 Text en Copyright © 2017 JCBN http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Liu, Huanhuan Zhong, Huijia Leng, Liang Jiang, Zhuoqin Effects of soy isoflavone on hepatic steatosis in high fat-induced rats |
title | Effects of soy isoflavone on hepatic steatosis in high fat-induced rats |
title_full | Effects of soy isoflavone on hepatic steatosis in high fat-induced rats |
title_fullStr | Effects of soy isoflavone on hepatic steatosis in high fat-induced rats |
title_full_unstemmed | Effects of soy isoflavone on hepatic steatosis in high fat-induced rats |
title_short | Effects of soy isoflavone on hepatic steatosis in high fat-induced rats |
title_sort | effects of soy isoflavone on hepatic steatosis in high fat-induced rats |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5612816/ https://www.ncbi.nlm.nih.gov/pubmed/28955124 http://dx.doi.org/10.3164/jcbn.16-98 |
work_keys_str_mv | AT liuhuanhuan effectsofsoyisoflavoneonhepaticsteatosisinhighfatinducedrats AT zhonghuijia effectsofsoyisoflavoneonhepaticsteatosisinhighfatinducedrats AT lengliang effectsofsoyisoflavoneonhepaticsteatosisinhighfatinducedrats AT jiangzhuoqin effectsofsoyisoflavoneonhepaticsteatosisinhighfatinducedrats |